Hardcover
Compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the essential international regulatory documents. This book provides coverage of the process of nonclinical safety assessment and comprehensive reviews of each type of biopharmaceutical.

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

$497.14

  • Hardcover

    432 pages

  • Release Date

    18 July 2013

Check Delivery Options

Summary

Current Approaches for the Preclinical Development of Novel Biologics, Biosimilars and Specialty Biologics

Book Details

ISBN-13:9780123948106
ISBN-10:012394810X
Author:Danuta Herzyk, Lisa M. Plitnick
Publisher:Elsevier Science Publishing Co Inc
Imprint:Academic Press Inc
Format:Hardcover
Number of Pages:432
Release Date:18 July 2013
Weight:1.08kg
Dimensions:191mm x 235mm
A-Format
B-Format
C-Format
Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics by Danuta Herzyk - ISBN: 9780123948106
191 × 235 mm
A4
mm / in
What They're Saying

Critics Review

“…brings nonclinical testing of biological and follow-on biological drugs, vaccines plus cell and gene therapy drugs right up to date. It is written in a very readable, yet highly scientific manner and most of the relevant publications…on the topic are referenced…Overall, a ‘must read’ book for all in the nonclinical field of developing biological drugs.” –btsNews, June 2014”Researchers in pharmaceuticals, toxicology, and other biological sciences summarize the current status of developing medicines from biological material, pointing out where the process is different from developing small-molecule medicines and where it is the same. The topics include regulatory guidelines and their application in the non-clinical evaluation of biological medicines, early de-risking strategy for novel biotherapeutics…” –Reference & Research Book News, December 2013

About The Author

Danuta Herzyk

Dr. Lisa M. Plitnick is a Distinguished Scientist in Nonclinical Drug Safety, Merck Research Laboratories, Merck and Co., Inc. Lisa joined Merck in 2002 and currently serves as the Therapeutic Area Lead for Vaccines and a Nonclinical Safety Leader on vaccine and biologic development teams spanning early and late development. Lisa is also the Scientific and Regulatory Advisor for the in Vivo Biologics Release Testing Group in the Merck Manufacturing Division. Lisa co-edited the first edition of this book, Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics and has written and/or contributed to book chapters and peer-reviewed journal articles on biologics and vaccines. Lisa received a M.S. and Ph.D. in Immunology from the Albany Medical College. Following her graduate work she did a postdoctoral fellowship with a focus on Immunotoxicology in the Curriculum in Toxicology at the University of North Carolina in cooperation with the US Environmental Protection Agency, Dow Chemical and DuPont.

Returns

This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.